Skip to main content
Clinical Trials/NCT02524470
NCT02524470
Completed
Not Applicable

Feasibility Study for Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting v1.0

LifeWatch Services, Inc.1 site in 1 country19 target enrollmentJuly 2014
ConditionsVital Signs

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vital Signs
Sponsor
LifeWatch Services, Inc.
Enrollment
19
Locations
1
Primary Endpoint
Composite Outcome Measure - 100% Successful Vital Signs Acquisition
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

To assess the feasibility and usability of the Vital Signs Patch (VSP) System in the in-patient hospital setting to monitor vital signs using a patch, brain, gateway, and console. The VSP System will be incorporated into the study site's Information Technology infrastructure.

Detailed Description

The primary objective of this clinical feasibility study is to evaluate the feasibility of the Vital Signs Patch System (VSP). The VSP will be incorporated into the study site's Information Technology infrastructure and worn by in-patients for a minimum of 3 days and for the duration of their hospital stay up to 7 days. The VSP will take and monitor vital signs in addition to the normal equipment the facility uses to monitor and take vital signs. This study will not be assessing safety and no comparator groups will be used. As this study will not be treating any particular disease or condition, no randomization or blinding is required. Subjects will be chosen as they are admitted in accordance with the general population characteristics, inclusion and exclusion criteria and willingness to sign the Informed Consent. This clinical study involves a device with no additional drugs administered. During this study, a single VSP System patch will be worn for up to 48 hours. The first patch will be placed using the NEHB configuration. After the first 48 hours, the NEHB-configured patch will be replaced with a new patch in the PAL configuration. The second patch can remain on the subject for the duration of the subject's hospital stay, or up to seven (7) consecutive days. Individual patient use will determine the duration of time that the second patch can be worn.

Registry
clinicaltrials.gov
Start Date
July 2014
End Date
July 17, 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult male and female in-patients with vital signs considered 'stable' by clinical caregivers.

Exclusion Criteria

  • Pediatric patients
  • Female patients who are pregnant
  • Patients with internal or external defibrillators
  • Patients who have undergone surgery and still have a fresh incision on the chest.
  • Patients with skin damage on the chest such as burns, irritation, infections, wounds, etc.
  • Patients in the Critical Care Unit (CCU)
  • Patients who otherwise satisfy any of the contraindications associated with the VSP system.

Outcomes

Primary Outcomes

Composite Outcome Measure - 100% Successful Vital Signs Acquisition

Time Frame: Up to seven days

Successful acquisition of Temperature, Heart Rate, ECG, Respiration, and SpO2 daily for the inpatient stay of the subject up to seven days. Success is achieved if all vital signs are obtained on a study participant. It is a composite result.

Secondary Outcomes

  • Composite Outcome Measure - Adhesive Performance - Measurement of skin irritation resulting from adhesive used with electrodes.(Up to seven days)

Study Sites (1)

Loading locations...

Similar Trials